0
Es befinden sich keine Waren im Warenkorb !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Start > Cell > 4-1BB > CHEK-ATP038

HEK293/Human 4-1BB / TNFRSF9 Stable Cell Line

Order Now

  • Description
    HEK293/Human 4-1BB / TNFRSF9 Stable Cell Line
  • Application

    Binding assay by FACS and cell based ELISA

  • Growth Properties
    Adherent
  • Selection Marker
    Hygromycin B(300 μg/mL)
  • Culture Medium
    DMEM medium + 10% FBS
  • Freeze Medium
    10% DMSO + 90% FBS
  • Quantity
    1 vial contains at least 5x10^6 cells in 1 ml of 10% DMSO in FBS.
  • Storage
    Frozen in liquid nitrogen.
  • Mycoplasma Testing
    Negative
  • Sterility Testing
    Negative
  • Instructions for Use
    See data sheet for detailed culturing and assay protocol.
Receptor Assay
 4-1BB FACS

FACS assay shows that Monoclonal UreluMab antibody, Human IgG4 can bind to HEK293/Human 4-1BB / TNFRSF9 Stable Cell Line (CHEK-ATP038). HEK293/Human 4-1BB / TNFRSF9 Stable Cell Line was red line, Negative control HEK293 cells was grey line(QC tested).

Please contact us if you are interested in related cell pool service.

  • Background
    4-1BB is also known as CD137, tumor necrosis factor receptor superfamily member 9 (TNFRSF9), induced by lymphocyte activation (ILA), is a co-stimulatory molecule of the tumor necrosis factor (TNF) receptor superfamily. CD137 can be expressed by activated T cells, but to a larger extent on CD8 than on CD4 T cells. In addition, CD137 expression is found on dendritic cells, follicular dendritic cells, natural killer cells, granulocytes and cells of blood vessel walls at sites of inflammation. The best characterized activity of CD137 is its costimulatory activity for activated T cells. Crosslinking of CD137 enhances T cell proliferation, IL-2 secretion survival and cytolytic activity. Further, it can enhance immune activity to eliminate tumors in mice. CD137 can enhance activation-induced T cell apoptosis when triggered by engagement of the TCR/CD3 complex. In addition, 4-1BB/4-1BBL co-stimulatory pathway has been shown to augment secondary CTL responses to several viruses, and meanwhile augment anti-tumor immunity. 4-1BB thus is a promising candidate for immunotherapy of human cancer. CD137 has been shown to interact with TRAF2.
  • Permits & Restrictions
    This cell line is provided for research use only. It is not intended for any animal or human therapeutic use, any human or animal consumption, or any diagnostic use. You are not allowed to share, distribute, sell, modify, sublicense, or otherwise make this cell line available for use to other laboratories, departments, research institutions, hospitals, universities, or biotech companies. AcroBiosystems does not warrant the suitability of this cell line for any particular use, and does not accept any liability in connection with the handling or use of this cell line.
  • Clinical and Translational Updates

Comments (0)


Voraussichtlicher Liefertermin für vorrätige Produkte: 2 Arbeitstage

Price(EUR) : €3540.00

Promotion & Exhibitions



Drug Development Status

  • Number of Launched Drugs:0 Details
  • Number of Drugs in Clinical Trials:71 Details
  • Latest Research Phase:Phase 3 Clinical

Datasheet & Documentation

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

totop

Nachricht schicken